Approved for use through 150/10022, OMB 0651-0031

U.S. Patent and Trademark Officer U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Officer U.S. DEPARTMENT OF COMMERCE

OF COMMERC

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of 2

	acceptable and a valid OMB control number
	Complete if Known
Application Number	UNKNOWN
Filing Date	CONCURRENT
First Named Inventor	CONCURRENTLY HEREWITH
Group Art Unit	Rafael Herrmann et al.
Examiner Name	UNKNOWN
	UNKNOWN
Attorney Docket Number	BB1367 US CNT

Examiner C Initials * N		tie item (book, magazine, journal, social and title of the article (when appropriate	Γ
SY	1	J. M. SABATIER ET AL., Int. J. Peptide Protein Rec.	
	2	Specific for Ca2-a-Specific for	
	3	BARBARA SELISKO ET AL	
$\perp$	4	Nodus Hoffman consistue a Subfamily of Potessium-channel-blocking Scorpion Toxins  FATIMA LARABA-DJEBARI ET AL., Journ. of Biol. Chem., vol. 289(52):32835-32843, 1994, The Kallotoxin  Family Enlarged	
$\perp$	5	ERIC BUSINE ET AL., J. Peptide Res., vol. 45-54-55, 1997. Characterization of a New Family of Town-Like JOSE C. MARTINE CT. L. 1997. Characterization of a New Family of Town-Like JOSE C. MARTINE CT. 1997. The Complete State New York Complete New	
$\perp$	6	JOSE C. MARTINS ET AL., FEBS Letters, vol. 280(2):249-253, 1980, Solution Conformation of Leiturotoxin I  Lip possion and the conformation of Leiturotoxin I	
$\perp$	7	J.P. ROSS ET.A.L., Toxicon, vol. 23(1):113-125, 1885. Characterization of Ten Porteins from the Venom of the Monoccan Scorpion Androctonus Mauretanicus Mauretanicus, Six et Which are Toxic to the Mouse D. L. MARSHALL ET.A.I. Toxic 101.	
	8	D. L. MARSHALL ET AL., Toxicon, vol. 32(11):1433-1443, 1994, Neuromuscular Effects of Control Mouse	
Ш	9	CONCLET AL, Toxicon, vol. 32(11):1433, 1443, 1949, Neuronuscular Effects of Some Potassium Delaction Toxicon from the Venom of the Scorpton Leiunis Quinquestriatus Hebreus E. Z.OTKIN ET AL., Archives of Biochem, and Biochim, vol. 24(2):273-278, 1985, An Excitatory and a Standard Insect Toxic from Scorpton Venom book Affect Sodium Conductance and Possess a Common Binding Sec. 24(2):1546-1546.	
	10	E. ZLOTKIN ET AL., Biochimie, vol. 53:1073 1070 1070	
6	11	Venom of the Scorpion Androcenus Australia Hector  National Center for Biotechnology Information General Identifier No. 2958750, 8/5/98	

			2000/00, 6/3/98	1
Examiner	A 14 (1)			
Signature	g. Godberg	Date	21051	
EXAMINER: Initial	If reference considered, whether or not citation is in conformal copy of this form with next communication to apply	Considered	3/25/03	- 1
considered. Include	copy of this form with next communication is in conforma	nce with MPEP 609 Dec	and the same	

EXAMINER: Initial if inference considered, whether or not citation is in conformance with MPEP 609. Draw line strough citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any Washington, DC 20231. OD NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Petents,



Approved for use through 10:01:2002 ONB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Papowork Reduction Act of 1966, no paraces are required to respond to a collection of information unless 10 orbifers a velo OMB cord number

Substitute for form 1449A/PTO

and the same control number
Complete if Known
UNKNOWN
CONCURRENTLY HEREWITH
Rafael Herrmann et al.
UNKNOWN
UNKNOWN
BB1367 US CNT

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

Exam	iner	Cite	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.) of	_
Initials *		No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		1	National Center for Biotechnology Information General Identifier No. 1173377, 2/1/96	╁
4	_	2	National Center for Biotechnology Information General Identifier No. 1711347, 5/30/00	$\vdash$
4	4	3	National Center for Biotechnology Information General Identifier No. 1711349, 5/30/00	-
4	4	4	National Center for Biotechnology Information General Identifier No. 134302, 10/1/00	-
4	$\perp$	5	GARY G. CHIOCHI ET AL., Journ. of Biol. Chem., vol. 263(21):10192-10197, 1988, Purification and Characterization of a Unique, Potent Inhibitor of Apamin Binding from Leitings Outgoing Medical Characterization and	_
4	$\perp$	6	PATRICK AUGUSTE ET Al., Journ. of Biol. Chem., vol. 265(8):4753-4759, 1990, Leiurotoxin I (Scyllatoxin), a  Peptide Ligand for Ca2+-activated K+ channels	
$\perp$	$\perp$	7	National Center for Biotechnology Information General Identifier No. 134379, 11/1/95	_
$\perp$	$\perp$	8	National Center for Biotechnology Information General Identifier No. 1173380, 11/1/95	
$\perp$		9	National Center for Biotechnology Information General Identifier No. 4389290, 6/16/98	
L	1	0	ERIC BLANC ET AL., Blochemistry, vol. 37:12412-12418, 1998, Solution Structure of Two New Toxins from the Venom of the Chinese Scorpion Bulthus Martensi Karech Blockers of Potassium Channels	
<u> </u>	11		MARIA L. GARCIA ET AL., Blochemistry, vol. 33.6834-6839, 1994, Purification and Characterization of Three Inhibitors of Vottage-Dependent K+ Channels from Leirura quinquestitatus var. hebraeus Venom	
	1	- 1	ta. neuraeus venom	_

Signature 'EXAMINED: Initial	S. Doldberg	Date Considered	3/24/03	
considered, Include	I if reference considered, whether or not citation is in conformal e copy of this form with next communication to applicant.	nce with MPEP 609. Dr.	w line through citation if not in conformance and no	

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any omments on the amount of time you are required to complete this form is mould be sent to be forched information. Doc 2023.1. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commission for Palentis, Washington, DC 20231.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Panerance D is a valid OMB control number

To mak Newtonia	1995, no persons are movement to see and in additional Villice: U.S. DEPAR
Substitute for form 1449A/PTO	or 1995, no persons are required to respond to a collection of information unless it contains
	Complete if Know

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet of 1

and the value of the control nu						
	Complete if Known	_				
Application Number	UNKNOWN					
Filing Date	CONCURRENTLY HEREV					
First Named Inventor	Paral Hammer	VITH_				
Group Art Unit	Rafael Herrmann et al. UNKNOWN					
Examiner Name	UNKNOWN					
Attorney Docket Number		_ oc				
, sact realings	BB1367 US CNT	25				

				U.S. PATENT DOCU	MENTE	
Examiner	Chr	U.S. Patent D	cument	THE POCO	MENIS	
Initials *	Cite No.1		Code <sup>2</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevan
व्य	_ 1	4,925,664	T.,		MM-DD-YYYY	Passages or Relevant Figures Appear
			+	Jackson et al.	05/15/90	
			+			
			+			
			-			
-						
	-+					
-	-+					

Examiner	Cite	Fon	eign Patent Do	cument	N PATENT DOCU			
Initials*	No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant	
32		World	95/03065		Merck & Co., Inc.		Figures Appear	T <sub>e</sub>
yu		Europe	0 374 753		O'this G Co., Inc.	02/02/1995		
~u l					Ciba-Geigy AG	12/15/1989		
81		World	94/28114		American Cyanamid Company	12/8/1994		
				-				
				+				
+								
+								
				1				

Examiner Signature	& Goldburg		3/25/03	
considered. Include	if reference considered, whether or n copy of this form with next communi	not citation is in conformance with MPEP 609.	Draw line through citation if not in conformance	e and not

on is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chef Information Officer, U.S. Patient and Trademark Officer, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patients, Washington, DC 20231

<sup>\*</sup>Unique cliation designation number, \* See attached Kinds of U.S. Patent Documents. \*Enter Office that issued the document, by the two-letter code (WIPO Unique citation designation number: "see mationine Numbs of U.S.). Plastic DOCUMENTAL : Emist Unice that the source was documental, by the restriction of the Standard ST.3). For Japanese patient documents, the Indication of the year of the religion of the Emperor must precede the sent Summer (3.1-a), for department securiorists, we institute to use year or use reign or the critiquor most present the stress manager or the pursuing document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to piace a